Editas up on positive initial data from blood disorder treatment trials

Editas Medicine

09/06/2023 13:58

** Shares of gene editing company Editas Medicine Inc
 EDIT.O  up 3.5% at $9.94 before the bell
    ** Co reports positive initial safety and efficacy data from
two early-to-mid-stage trails for its experimental cell therapy,
EDIT-301, to treat two types of blood disorders
    ** Co says EDIT-301 was safe and well-tolerated when tested
in first four patients with sickle cell disease (SCD) and one
patient with transfusion-dependent beta thalassemia (TDT) 
    ** EDIT says all five patients treated with EDIT-301 showed
successful engraftment, which marks the start of the recovery
process as new cells start working properly and rebuild the
immune system
    ** Co adds that all four patients treated in SCD trial were
free of vaso-occlusive events since infusion, where sickled red
blood cells block blood flow to the point that tissues become
deprived of oxygen
    ** No serious adverse events occurred, and no adverse events
reported were related to treatment with EDIT-301 - co 
    ** Up to last close, stock up ~8% YTD

 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com;))